|4Aug 26, 4:18 PM ET

Wells David R. 4

4 · ENDRA Life Sciences Inc. · Filed Aug 26, 2019

Insider Transaction Report

Form 4
Period: 2019-08-22
Wells David R.
Chief Financial Officer
Transactions
  • Purchase

    Common Stock

    2019-08-23$1.55/sh+5,000$7,75010,000 total
  • Purchase

    Common Stock

    2019-08-22$1.56/sh+5,000$7,8005,000 total
Holdings
  • Common Stock

    (indirect: By StoryCorp Consulting)
    24,786
Footnotes (1)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.59, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION